Anti-VHL Rabbit Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - P40337

Core Product Specifications and Parameters

Biological Background: VHL Function and Localization

• VHL (von Hippel-Lindau disease tumor suppressor) is the substrate recognition subunit of the VCB-Cul2 E3 ubiquitin ligase complex, targeting proteins for proteasomal degradation. Related references: PMID:10944113 PMID:17981124 PMID:19584355

• Under normoxic conditions, VHL specifically recognizes hydroxylated hypoxia-inducible factor alpha (HIF-α) subunits, leading to ubiquitin-dependent degradation and repression of HIF-mediated transcriptional programs. Related references: PMID:10944113 PMID:17981124

• VHL also ubiquitinates and promotes degradation of alternative substrates, including ADRB2 and the mTORC1 scaffold RPTOR, thereby negatively regulating mTORC1 signaling. Related references: PMID:19584355 PMID:34290272

• The protein dynamically localizes to the cytoplasm, nucleus, cell membrane, and endoplasmic reticulum, enabling its participation in multiple signaling pathways and spatial regulation of ubiquitylation.

• VHL is predominantly expressed in adult and fetal brain and kidney—tissues susceptible to tumorigenesis upon VHL loss—underscoring its tissue-specific tumor suppressor role.

• The VHL gene produces multiple isoforms (including pVHL and G7) via alternative splicing and alternative translation initiation, which may exhibit distinct functional properties.

• As a well-established tumor suppressor, biallelic inactivation of VHL leads to constitutive HIF activation and is the driving event in von Hippel-Lindau disease and sporadic clear cell renal carcinoma.

Experimental Guidance and Technical Tips

• The immunogen region (amino acids 1–100 of human VHL) suggests the antibody recognizes the N‑terminus; consider epitope mapping if precise binding information is required.
• In western blotting (WB), expect a major band near 24 kDa; alternative isoforms or post‑translational modifications may produce additional bands.
• For immunohistochemistry (IHC-P) and immunofluorescence (IF/ICC), antigen retrieval conditions and fixation protocols should be optimized for the tissue or cell type of interest.
• The antibody cross-reacts with mouse and rat VHL; validate in the relevant species model before quantitative assays.
• For ELISA applications, pair with a capture antibody or use as a detection reagent after confirming compatibility with the assay format.
• As a polyclonal antibody, lot-to-lot consistency should be verified via positive control lysates or recombinant protein.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your dedicated partner for sourcing high-quality IVD raw materials, offering this anti-VHL rabbit polyclonal antibody alongside a broad portfolio of characterized antibodies, bulk reagents, and ancillary proteins for ubiquitination and cancer research. From validated antibody pairs to customized sourcing of rare targets, our one-stop supply capabilities help accelerate your assay development from concept to clinical application.